semaj83/ctmatch_classification huggingface dataset:
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Beta Blocker Intolerance; Congestive Heart Failure Patients on optimal therapy for heart failure (diuretics, ACE inhibitors and aldosterone antagonists), with stable dose in the previous month Successfully implanted with CRT-D according to current European Society of Cardiology (ESC) guidelines New York Heart Association (NYHA) functional class: II, III and IV Left Ventricular Ejection Fraction (LVEF) ≤ 35% Duration of ventricular depolarization wave (QRS) ≥ 120ms (NYHA III or IV) or ≥ 150ms in NYHA II Patients with chronic atrial fibrillation will be eligible for the study only if they undergo ablation  years or above  Failure to comply with the scheduled follow-up Life expectancy less than 12 months  Pregnant women Tricuspid valve mechanics Severe aortic stenosis or other valve disease  Patients already receiving CRT
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Chronic Obstructive Pulmonary Disease Male and female adults (40 ≤ age ≤ 80 years) with a diagnosis of COPD Current smokers or ex-smokers A post-bronchodilator FEV1 < 60% of the predicted normal value and a post-bronchodilator FEV1/FVC < 0.7 Positive response to the reversibility test at screening defined as change in FEV1 ≥ 5% BDI score ≤ 10 Patients free of exacerbations for at least 1 month  Pregnant or lactating women Diagnosis of asthma Patients treated for exacerbations in the 4 weeks prior to screening visit Patients treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study or if taken as PRN Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia Known respiratory disorders other than COPD Patients who have clinically significant cardiovascular condition
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sleep Disordered Breathing Heart Failure Heart failure with reduced ejection fraction (<40%) Either no significant sleep disordered breathing or moderate to severe CSA Able to consent to the study Ambulatory Aged 18-100 years  Patients on Non-Invasive Ventilation Predominant OSA Unable to consent or attend for the study
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Gastroesophageal Reflux Disease GERD Gastroparesis Male or female Age 12 and older Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy Patients must have a comprehensive evaluation to eliminate other causes of their symptoms Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including increased prolactin levels extrapyramidal side effects breast changes cardiac arrhythmias including QT prolongation and death There is a potential for increased risk of adverse events with the drugs listed in the domperidone protocol addendum  History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged QTc (QTc> 450 milliseconds for males, QTc>470 milliseconds for females) Clinically significant electrolyte disorders Gastrointestinal hemorrhage or obstruction Presence of a prolactinoma (prolactin-releasing pituitary tumor) Pregnant or breast feeding female Known allergy to domperidone
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Decompensated Heart Failure Congestive Heart Failure Compensated Age ≥ 18 years, AND Written informed consent by patient or nearest relative where appropriate, AND Either Referred for echocardiography, OR At least one typical symptom and one typical sign consistent with possible heart failure, OR Healthy volunteers  Age <18 years Prior enrollment in study Patients with known or suspected pregnancy
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Asthma History of asthma ≥ 5 years and diagnosed before 40 years old Uncontrolled asthma on low-medium doses of Inhaled CorticoSteroid (ICS) with ACQ (Asthma Control Questionnaire) ≥1.5 Pre-bronchodilator FEV1 ≥40% and <90% of their predicted normal value Positive reversibility test  Pregnant or lactating women Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) Patients treated for asthma exacerbation in the 4 weeks prior to study entry Patients who are in therapy for gastroesophageal reflux disease Patients who have a clinically significant cardiovascular condition
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure years and older History of heart failure with an LVEF (less than OR equal to) < 0.35 for at least 6 months OR an LVEF < 0.45 with left ventricular internal end diastole (defined by a diameter of more than 2.9 cm per square meter of body surface area OR more than 6.5 cm on the basis of echocardiography) New York Heart Association (NYHA) Class II-IV Background heart failure therapy that includes angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), and beta blockers (BBs) for at least 3 months (or documentation of intolerance to ACEi/ARBs and BBs)  No history of intolerance to either nitrates or hydralazine No treatment with the combination of hydralazine and nitrates for the previous 3 months No revascularization or myocardial infarction within last 90 days Can not be enrolled for at least 90 days after receiving cardiac resynchronization therapy (CRT) AND must have an LVEF (less than OR equal to) < 0.35 at least 3 months after CRT Presence of clinically significant valvular heart disease, hypertrophic or restrictive cardiomyopathy, active myocarditis, or uncontrolled hypertension Women who are currently pregnant, planning on becoming pregnant in the next two years, or those who do not agree to prevent pregnancy
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Congestive Heart Failure Heart Failure, Diastolic Heart Failure, Systolic Elderly Frail Guideline Adherence All patients who admitted to the participating centers due to acutly decompensated CHF defined by modified Framingham Patients who underwent heart failure treatment including intravenus drug
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure University of Michigan patients hospitalized for the treatment of heart failure, within the past 30 days Patients must be receiving an oral loop diuretic on their home regimen or have received intravenous loop diuretic during the index hospitalization at the time of enrollment Patients must have an assessment of left ventricular function within the previous 2 years Patients must have LVEF ≤ 40%, or LVEF >40 with evidence of left atrial enlargement (LA dimension > 40 mm), BNP > 200 ng/ml or PCW > 18 mmHg  Prisoners Residents of long term nursing facilities Enrollment into a hospice program Receiving dialysis Patients with dementia Patients with dGFR less than 20ml/min Patients being worked up for heart surgery Patients being worked up for heart transplant Patients being evaluated for revasuculariztion Patients being evaluated for heart valve intervention
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Patients admitted with symptomatic heart failure, diagnosed within 2 years Diagnosis of congestive heart failure using the modified Framingham Simultaneous presence of at least 2 major or 1 major criterion in conjunction with 2 minor or a previous clear diagnosis of heart failure Major Paroxysmal nocturnal dyspnea or orthopnea Neck vein distention Rales/Crackles (>10 cm from base of lungs) Acute pulmonary edema S3 gallop Increased central venous pressure (>16 cm H2O at right atrium)  Patients unable to provide blood sample Patients unable to provide consent Patient with life expectancy of less than 6 months, or has major co-morbidities Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial Participants who have participated in another research trial involving an investigational product in the past 30 days
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Preeclampsia Exposed cases African American women who are admitted to the obstetrical unit with a concern for severe preeclampsia. Patients must be preterm (23-36 6/7 weeks) with a live singleton gestation and at least 18 years old. Women will baseline chronic hypertension and women on magnesium will be included  Non-African American women, and African women with concern for severe preeclampsia who are admitted 23 weeks or 37 weeks. Women in labor will be excluded. Women with preexisting cardiovascular disease and women who are current smokers will be excluded Unexposed controls African American women obtaining prenatal care in our outpatient setting who meet matching as noted above Non-African American women and women who are not receiving care at our institution All women who do not speak English and who are unable to be consented will be excluded
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Heart Failure Hospitalized for heart failure Prescribed loop diuretic medication at discharge  Age less than 21 years New York Heart Association Class IV heart failure Terminal illness (<6 mo prognosis) Unable to self-administer medications due to mental illness or cognitive impairment Non-English/Spanish speaking Discharged to an institutional setting (e.g., nursing home) Cardiologist or primary care provider refusal Unavailable for follow-up No access to telephone Enrolled in another cardiac trial
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure With Reduced Ejection Fraction Key Adult patients (18 years or older); must give written informed consent before any assessment is performed Patients with a diagnosis of Chronic heart failure (CHF) NYHA class II-IV and reduced ejection fraction (LVEF =< 35%) Patient had a hospitalization for HF within the last 12 months Patients must be on an angiotensin converting enzyme inhibitors (ACEIs) or an angiotensin receptor blocker (ARB) at a stable dose for at least 4 weeks Patients must be treated with a β-blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks Key  The patient is eligible for participation in any of the Investigational Medicinal Product's ongoing clinical trials The patient has recently completed a clinical trial that has been terminated and other options (e.g., trial extensions, amendments, etc.) are available to continue a similar treatment The patient is being transferred from an ongoing clinical trial for which the patient is still eligible for participation History of hypersensitivity or allergy to LCZ696 or to any of its metabolites; to drugs of similar chemical classes, ARBs, or neutral endopeptidase (NEP) inhibitors; as well as known or suspected contraindications to LCZ696 Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer Previous history of intolerance to recommended target doses of ARBs Known history of angioedema Requirement of concomitant treatment with both ACEIs and ARBs Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy) Symptomatic hypotension and/or a SBP less than 100 mm Hg
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure 18 years or older patients with congestive heart failure Hypervolemic by at least 2 of the following 1) Peripheral edema; 2) jugular venous distention greater than 7 cm; 3) radiographic pulmonary edema or pleural effusion; 4) enlarged liver or ascites; 5) pulmonary rales, paroxysmal nocturnal dyspnea or orthopnea Diuretic resistance as defined by loop diuretic requirements of furosemide greater or equal to 160 mg IV total daily dose or equivalent dose of torsemide or bumetanide. ( 1 mg bumetanide = 10 mg torsemide = 20 mg furosemide) Estimated glomerular filtration rate (eGFR) of > 30ml/min. according to the MDRD Study equation at the time of admission Female patients of child bearing potential must have a negative urine pregnancy test to be eligible  Acute coronary syndrome Patients with a baseline eGFR < 30 ml/min according to the MDRD equation Baseline potassium serum concentration 5.3 meq/L Requirement for intravenous pressors Systemic infection Patients with concomitant end-stage liver disease Significant valvular disease Patients with pulmonary embolism Patients with high output heart failure Pregnant patients
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Obstructive Sleep Apnoea Pregnancy Pregnant women Body mass index ≥ 40 at first midwife appointment Women ≥ 18 years of age  Pre-existing obstructive sleep apnoea on treatment Pre-existing restrictive or obstructive respiratory disease Women with another cause of sleep apnoea (e.g. central sleep apnoea) Women under 18 years of age Women who do not provide or refuse consent Women lacking capacity to consent
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Heart Failure Patient with "de novo" heart Failure and LVEF <= 40% admitted in hospital, without contraindications for BB prescription with cardiologist up-titration prescription and without having achieved BB target dose previous discharge and signing informed consent  Contraindications for BB Living in a nursing home Life expectancy < 6 months Unable to self-care or mental disease without caregiver Unable to weight Without phone Unable to go to clinic visit
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Bronchial Secretion Retention Intubated patients (with and without mechanical ventilator support) with secretion 1.5 ml/h, If the patients are breathing with mechanical ventilation, the PEEP level must be less than 6 centimeter of water and one of following Clinical and radiologic diagnosis of pulmonary infection Acute or chronic airway inflammation disease such as pneumonia, bronchiectasis, chronic obstructive pulmonary disease or chronic bronchitis and at least one sign of secretion accumulation in bronchial such as medium-coarse crackle, wheezing, persistent rhonchi and decrease breath sound Stable of cardiopulmonary function at least 2 days before the study and the patients don't receive the vasopressors drug within 5 days before collects the data Stable of hydration status or positive fluid balance at least 2 days before collects the data Ability to breathe or tolerate spontaneously breathing trial with T-piece at least 30 minutes with fraction of inspired oxygen less than 0.4 and without developing hypoxemia Good conscious and well cooperation  Pneumothorax (nontreated) Massive hemoptysis Acute myocardial infarction (with angina chest pain) High intracranial pressure (>20 mm Hg) Major arrhythmia
Patient description: A 65 yo African-American male with shortness of breath related to exertion that has been worsening over the past three weeks. He also has difficulty breathing when lying flat and has started using two to three extra pillows at night. Significant physical exam findings include bibasilar lung crackles, pitting ankle edema and jugular venous distension.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure age of 18 years or older hospital admission for hypervolemic decompensated heart failure complicated by loop diuretic resistance hour telemetry monitoring on an inpatient ward basic metabolic panel laboratory assessment twice daily during the study period Hypervolemia will be diagnosed by the admitting provider as either (i) pulmonary artery catheterization with a pulmonary capillary wedge pressure greater than 19mmHg plus a systemic physical exam finding of hypervolemia (peripheral edema, ascites, or pulmonary edema on auscultation) or (ii) in the absence of pulmonary artery catheterization data 2 of the following signs or symptoms: peripheral edema ascites, jugular venous pressure > 10mmHg, or pulmonary edema on chest x-ray Loop diuretic resistance is defined as a provider decision to pursue combination diuretic therapy because of failure to reach provider defined adequate diuresis (can not exceed urine output of 2 L in past 12 hours) despite receipt of an intravenous loop diuretic dose of a furosemide equivalent of at least 240mg/day over at least the past 12 hours (40mg furosemide = 20mg torsemide = 1mg bumetanide)  decision to pursue hemodialysis by a nephrologist estimated glomerular filtration rate by the MDRD equation < 15ml/min/m2 systolic blood pressure < 85mmHg pregnancy serum potassium < 3.0mEq/L serum sodium > 145mEq/L or < 130mEq/L severe malnutrition advanced liver disease inability to perform standing weights inability to collect and measure urine with either a foley catheter or urine collection containers